Integrated BioPharma — Fiscal Year 2026 Earnings Summary

Financial Performance

• Quarterly revenue for the period ended June 30, 2026, was $9.8 million, a 31.0% decrease from $14.2 million in the same quarter of 2025.
• Fiscal year revenue for the period ended June 30, 2026, was $43.9 million, a 19.3% decrease from $54.4 million in the fiscal year ended June 30, 2025. (Note: The financial table lists fiscal year revenue as $48.9 million for 2026 and $54.4 million for 2025).
• The company reported an operating loss of $0.9 million for the quarter ended June 30, 2026, compared to operating income of $0.6 million in the prior year quarter.
• The company reported an operating loss of approximately $2.7 million for the fiscal year ended June 30, 2026, compared to operating income of $2.0 million in the prior fiscal year.
• Net loss for the quarter ended June 30, 2026, was approximately $1.4 million ($0.04 per share), compared to a net loss of $0.2 million ($0.01 per share) in the prior year quarter.
• Net loss for the fiscal year ended June 30, 2026, was approximately $2.8 million ($0.09 per share), compared to net income of $0.8 million ($0.03 per share) in the prior fiscal year.
• Gross profit for the quarter ended June 30, 2026, was $28,000, down from $1.5 million in the prior year quarter.
• Gross profit for the fiscal year ended June 30, 2026, was $800,000, down from $5.6 million in the prior fiscal year.
• Selling and administrative expenses were $897,000 for the quarter and $3.5 million for the fiscal year, remaining relatively flat compared to $880,000 and $3.5 million, respectively, in the prior year periods.

Business Segments and Product Lines

• Revenue from the company's two largest customers in the Contract Manufacturing Segment represented approximately 90% of total revenue in the fiscal year ended June 30, 2026, compared to 84% in the fiscal year ended June 30, 2025.

Management Commentary and Tone

• Co-Chief Executive Officers Riva Sheppard and Christina Kay stated that revenue decreased by approximately 19% in the fiscal year ended June 30, 2026, compared to the prior fiscal year.
• Management highlighted the high concentration of revenue from the two largest customers in the Contract Manufacturing Segment.

Other Key Points

• The company is engaged in the manufacturing, distribution, marketing, and sales of vitamins, nutritional supplements, and herbal products.
• The press release includes a standard disclaimer regarding forward-looking statements and risks, including potential loss of market share, competition, regulatory changes, and the loss of significant customers or suppliers.
• The company trades on the OTCQX market under the ticker symbol INBP.